北京若生智能科技有限公司
Drug Database
PI

piroxicam suppositories (Riacen)

✓ Approved

Chiesi Farmaceutici S.p.A. · PTGS1 · 小分子

什么是 piroxicam suppositories？

piroxicam suppositories 是一种小分子，由Chiesi Farmaceutici S.p.A.研发。该药已获批，用于治疗相关适应症，给药途径：Rectal。

药物档案

商品名Riacen
公司Chiesi Farmaceutici S.p.A.
药物类别小分子
分子靶点PTGS1, PTGS2
给药途径Rectal
状态Approved
来源： ClinicalTrials.gov, Chiesi Farmaceutici S.p.A.

作用机制

分子靶点

piroxicam suppositories 作用于 2 个分子靶点：

PTGS1prostaglandin-endoperoxide synthase 1 (COX3, PCOX1)
PTGS2prostaglandin-endoperoxide synthase 2 (GRIPGHS, hCox-2)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

piroxicam suppositories 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Hepatobiliary disordersHepatitis✓ Approved

相关研究文献

PubMedExplore (New York, N.Y.)2026-09-03

Investigating the effect of sweet almond oil vaginal suppository on spontaneous and duration of labor in nulliparous women: A triple-blind clinical trial study.

Hosseini Balajourshari Parisa P, Karimi Fatemeh Zahra FZ, Salar Roshanak R, Mazloum Seyed Reza SR

Various pharmacological, herbal, and mechanical methods have been used to facilitate, However, evidence regarding the effects of vaginal sweet almond oil suppositories on labor outcomes remains limited. This study evaluated their effect on spontaneous labor and the duration of labor stages in nulliparous women at 40 completed weeks of gestation. This triple-blinded, randomized, placebo-controlled clinical trial was conducted between July 2023 and January 2024 in Mashhad, Iran. Eligible nulliparous women at 40+0 weeks of gestation received one vaginal suppository daily for up to seven consecutive days. The primary outcome was spontaneous onset of labor while secondary outcomes included the duration of the first, second, and third stages of labor. Data were analyzed using SPSS version 25. Independent-sample t-test, Chi-square test, and Mann-Whitney U test were used, as appropriate. A P value <0.05 was considered statistically significant. The rate of spontaneous labor rate was higher in the sweet almond group than in the placebo group (66.7% vs. 40%, P=0.03). The mean duration of the second stage of labor was significantly shorter in the sweet almond group than in the placebo group (P < 0.05), whereas no significant differences were observed in the duration of the active first or third stages of labor (P > 0.05). These findings suggest that vaginal sweet almond oil suppositories may facilitate the onset of labor and shorten the second stage of labor in low-risk nulliparous women at 40+0 weeks of gestation. Larger multicenter trials are warranted to confirm these findings before routine clinical use can be recommended.

PMID 42685572
阅读全文 →
PubMedUrologiia (Moscow, Russia : 1999)2026-09-03

[Pilot study of bovhyaluronidase azoximer in patients with acquired proximal seminal tract obstruction].

Gamidov S I I, Popova A Yu Y, Shatylko T V V

Acquired proximal seminal tract obstruction may develop as a result of infectious-inflammatory, post-traumatic, or iatrogenic lesions of the epididymis and proximal segments of the vas deferens. In bilateral disease, it leads to obstructive azoospermia. Surgical sperm retrieval and microsurgical reconstruction remain the principal approaches to infertility management; however, conservative treatment targeting the inflammatory and fibrotic component of obstruction is of practical interest. To carry out a pilot assessment of the potential effect of different dosage forms of bovhyaluronidase azoximer on semen parameters in patients with acquired proximal seminal tract obstruction. A total of 80 men with obstructive azoospermia caused by proximal seminal tract obstruction and associated infertility were examined. The patients were divided into two groups of 40 patients each. In the first group, bovhyaluronidase azoximer was administered as rectal suppositories at a dose of 3000 IU; in the second group, it was administered as a lyophilizate for intramuscular injection at a dose of 3000 IU. Follow-up examination and semen analysis were performed once, 95-105 days after the start of therapy. Statistical analysis was primarily descriptive; the proportions of patients with spermatozoa detected in the ejaculate were compared using Fishers exact test. Spermatozoa appeared in the ejaculate in 10 of 80 patients (12.5%). The median sperm concentration was 0.85 million/mL, the median total sperm count was 1.65 million, and the median total motile sperm count was 0.1815 million. In the suppository group, spermatozoa appeared in 6 of 40 patients (15.0%); in the intramuscular injection group, spermatozoa were detected in 4 of 40 patients (10.0%). The between-group difference was not statistically significant (p=0.737). The number of spermatozoa obtained was insufficient for natural conception; however, in selected cases it could be of practical value for cryopreservation and subsequent use in intracytoplasmic sperm injection programs. These results should be considered preliminary because of the pilot design, absence of a control group, and limited number of patients with a positive response. The obtained data suggest that bovhyaluronidase azoximer may be considered a potentially pathogenetically substantiated component of complex therapy in patients with proximal seminal tract obstruction. Further studies of appropriate methodological quality are required to clarify the clinical significance of these findings.

PMID 42687538
阅读全文 →
PubMedScientific reports2026-09-02

Sorafenib/piroxicam therapy with biomarker-defined survival benefit in canine muscle-invasive urothelial carcinoma.

Maeda Shingo S, Yokota Shohei S, Komori Mao M, Goto-Koshino Yuko Y et al.

Molecular-targeted therapies require biomarker-driven evaluation to optimize precision oncology strategies; however, translational models integrating clinical outcomes with mechanistic biomarkers are limited. Canine urothelial carcinoma shares molecular features with human muscle-invasive bladder cancer, including activation of VEGFR signaling, providing a valuable comparative oncology platform. Sorafenib is a multi-kinase inhibitor targeting VEGFRs, PDGFRβ, BRAF, and related pathways, but its therapeutic mechanisms and clinical benefit in urothelial carcinoma remain incompletely understood. In this study, 43 dogs with naturally occurring urothelial carcinoma received first-line sorafenib and piroxicam therapy. The overall response rate was 62.8%, with median progression-free and overall survival of 175 (range, 31-665) and 407 (range, 103-1,723) days, respectively. The results exceeded outcomes in historical controls treated with piroxicam alone. Treatment was generally well tolerated, with only three grade 3 adverse events and no grade 4-5 toxicities. Biomarker analyses revealed that treatment-induced hypertension and high tumor CX3CL1 mRNA expression were independently associated with improved overall survival, suggesting that effective VEGFR pathway inhibition and modulation of the tumor immune microenvironment contribute to clinical benefit. These findings support sorafenib-based therapy as a promising strategy for canine urothelial carcinoma and highlight the translational potential of biomarker-driven VEGFR-targeted approaches in precision oncology.

PMID 42680778
阅读全文 →
PubMedFrontiers in pediatrics2026-09-02

Salmonella Typhimurium infection complicating very early-onset inflammatory bowel disease presenting with Pseudo-intussusception: a case report.

Liu Qian Q, Yang Ling L, Sun Xuefeng X, Liu Yishan Y et al.

The clinical manifestations of acute non-typhoidal Salmonella infection can overlap with underlying very early-onset inflammatory bowel disease (VEO-IBD), complicating early differential diagnosis. We report a 5-year-old boy who presented with fever, paroxysmal abdominal pain, and high-volume watery hematochezia. Initial abdominal ultrasonography revealed a "concentric ring sign" mimicking intussusception, while laboratory tests concurrently demonstrated elevated serum total immunoglobulin E (IgE) levels. Subsequent water-soluble gastrointestinal contrast studies and computed tomography ruled out mechanical intestinal obstruction. Early endoscopy and mucosal biopsy revealed cryptitis and chronic active inflammation from the rectum to the sigmoid colon, and stool cultures isolated Salmonella Typhimurium, with serum total IgE peaking at 2965 IU/mL. Based on these clinical findings, the patient was diagnosed with concurrent acute Salmonella Typhimurium infection and VEO-IBD. The patient received a combined regimen of systemic intravenous cefotaxime sodium and localized therapy comprising dexamethasone retention enemas and mesalazine suppositories, with symptom resolution within 10 days. This case illustrates the value of multimodal imaging and early endoscopy in differentiating overlapping enteric infections from VEO-IBD, and suggests that integrating systemic antimicrobials with localized anti-inflammatory agents may be a feasible therapeutic strategy.

PMID 42682644
阅读全文 →
PubMedEpilepsy & behavior reports2026-08-19

Evaluation of the appropriateness of pediatric seizure Management in Primary Care Clinics.

Matsuda Shimpei S, Akiba Takato T, Kondo Natsumi N, Takegami Masayo M et al.

Effective management of any pediatric seizure event - not only febrile seizures - is a core requirement of pediatric primary care. In Japan, where the background prevalence of febrile seizures (FSs) is high (8-10% of children), pediatric primary care clinics may encounter status epilepticus (SE) requiring immediate antiseizure medication. Buccal midazolam was approved in Japan in December 2020. The pediatric rescue medication landscape in Japan differs substantially from many other countries: rectal diazepam gel is not approved, and intranasal diazepam was not yet on the market during the study period. To our knowledge, primary-care-level data on the incidence and management of in-clinic pediatric seizures in Japan remain limited. This multicenter retrospective observational study included pediatric patients (0-18 years) who experienced seizures during clinic visits at 32 primary care clinics in Japan between November 2023 and October 2024. Clinical data were extracted from electronic medical records. SE was defined as a generalized tonic-clonic seizure lasting ≥5 min. Statistical analyses included chi-square tests to assess the relationships between seizure onset time of day, monthly occurrence, and emergency transport. Among transported patients, the appropriateness of buccal midazolam administration was evaluated against pre-specified criteria based on the Japanese package insert. Of 967,417 eligible pediatric outpatient visits (after exclusion of 191,009 visits by patients aged >18 years), 132 (0.014%) involved an in-clinic seizure. Of these, 52 (39.4%) required emergency transport. No significant differences were observed in seizure occurrence across time of day (χ2(2, n = 132) = 0.32, p = 0.85) or months (χ2(11, n = 132) = 16.84, p = 0.11). Among the transported patients, 24 (46.2%) had SE (of whom 23 had febrile status epilepticus and 1 had an afebrile seizure following head trauma); seven (13.5%) had seizure clusters; the remainder did not meet criteria for SE, clusters, or focal seizures. Buccal midazolam was administered to 22 patients (42.3%) but was deemed appropriate for SE in only 14 (63.6%) of those administrations. Diazepam suppositories - a prophylactic, not a rescue, formulation in Japan - were administered in 19 (36.5%) cases, in some instances delaying buccal midazolam administration. All administered doses conformed to the age-stratified dosing schedule of the Japanese package inserts. Seizures in pediatric primary care occur sporadically and require continuous preparedness. Suboptimal management of SE, particularly delayed benzodiazepine administration and underutilization of buccal midazolam, was identified. Enhanced education focusing on SE recognition and appropriate medication use may improve the quality of seizure care in community pediatric settings.

PMID 42614528
阅读全文 →
PubMedJournal of visualized experiments : JoVE2026-08-18

A Model of Piroxicam-Accelerated Enterocolitis in Interleukin-10 Knockout Mice for Studying Inflammation-Induced Metabolic Alterations.

Ranjan Mihir M, Williams Justin J, Peng Lan L, Burstein Ezra E et al.

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the digestive tract affecting over 10 million individuals globally. While substantial research has focused on the immunologic mechanisms and consequences underlying IBD, less is understood about how mucosal inflammation contributes to metabolic dysregulation, including weight loss and reduced appetite. Here, the authors describe a mouse model of piroxicam-accelerated enterocolitis in interleukin-10-knockout (IL-10-KO) mice to study inflammation-induced metabolic dysregulation. IL-10-KO mice are known to develop spontaneous enterocolitis and have heightened susceptibility to enterocolitis triggered by infections or drugs. However, vivarium conditions and strain background have been reported as confounders in colitis development in this model. Piroxicam, a non-steroidal anti-inflammatory drug (NSAID), has been demonstrated to trigger or accelerate enterocolitis in animal models by increasing mucosal exposure to luminal bacteria. In this protocol, male and female IL-10-KO mice were fed a piroxicam-fortified diet in place of a regular chow diet. Food intake and body weight were measured daily to reflect whole-body metabolic alterations, along with clinical manifestations of enterocolitis such as diarrhea and rectal bleeding. The protocol is efficient and reproducible, inducing enterocolitis simultaneously in multiple mice, and allows assessment of metabolic dysregulation in an inflammatory bowel disease model. Further studies using this protocol may investigate the effects of enterocolitis on other components of metabolic dysregulation, such as energy expenditure and body composition, revealing broader connections between inflammatory bowel disease and host metabolism.

PMID 42611797
阅读全文 →

注册免费账户还可查看另外 6528 篇文献

免费注册查看全部文献 →

了解更多piroxicam suppositories